AAAAAA

   
Results: 1-25 | 26-49
Results: 1-25/49
DISPOSITION OF CREMOPHOR EL IN HUMANS LIMITS THE POTENTIAL FOR MODULATION OF THE MULTIDRUG-RESISTANCE PHENOTYPE IN-VIVO
Authors: SPARREBOOM A VERWEIJ J VANDERBURG MEL LOOS WJ BROUWER E VIGANO L LOCATELLI A DEVOS AI NOOTER K STOTER G GIANNI L
Citation: A. Sparreboom et al., DISPOSITION OF CREMOPHOR EL IN HUMANS LIMITS THE POTENTIAL FOR MODULATION OF THE MULTIDRUG-RESISTANCE PHENOTYPE IN-VIVO, Clinical cancer research, 4(8), 1998, pp. 1937-1942
ORAL TOPOTECAN GIVEN ONCE OR TWICE-DAILY FOR 10 DAYS - A PHASE-I PHARMACOLOGY STUDY IN ADULT PATIENTS WITH SOLID TUMORS
Authors: GERRITS GJH BURRIS H SCHELLENS JHM ECKARDT JR PLANTING AST VANDERBURG MEL RODRIGUEZ GI LOOS WJ VANBEURDEN V HUDSON I FIELDS S VONHOFF DD VERWEIJ J
Citation: Gjh. Gerrits et al., ORAL TOPOTECAN GIVEN ONCE OR TWICE-DAILY FOR 10 DAYS - A PHASE-I PHARMACOLOGY STUDY IN ADULT PATIENTS WITH SOLID TUMORS, Clinical cancer research, 4(5), 1998, pp. 1153-1158
ORAL TOPOTECAN GIVEN ONCE OR TWICE-DAILY FOR 10 DAYS - A PHASE-I PHARMACOLOGY STUDY IN ADULT PATIENTS WITH SOLID TUMORS
Authors: GERRITS GJH BURRIS H SCHELLENS JHM ECKARDT JR PLANTING AST VANDERBURG MEL RODRIGUEZ GI LOOS WJ VANBEURDEN V HUDSON I FIELDS S VONHOFF DD VERWEIJ J
Citation: Gjh. Gerrits et al., ORAL TOPOTECAN GIVEN ONCE OR TWICE-DAILY FOR 10 DAYS - A PHASE-I PHARMACOLOGY STUDY IN ADULT PATIENTS WITH SOLID TUMORS, Clinical cancer research, 4(5), 1998, pp. 1153-1158
CONSOLIDATION THERAPY FOR ADVANCED OVARIAN-CANCER - RESPONSE
Authors: VANDERBURG MEL
Citation: Mel. Vanderburg, CONSOLIDATION THERAPY FOR ADVANCED OVARIAN-CANCER - RESPONSE, Annals of oncology, 9(2), 1998, pp. 229-230
PHASE-I TRIAL OF IRINOTECAN (CPT-11) COMBINED WITH CISPLATIN (C) GIVEN ONCE EVERY 3 WEEKS TO PATIENTS WITH SOLID TUMORS
Authors: DEJONGE MJA SPARREBOOM A PLANTING AST VANDERBURG MEL DEBOERDENNERT MM DEBRUYN P JACQUES C VERWEIJ J
Citation: Mja. Dejonge et al., PHASE-I TRIAL OF IRINOTECAN (CPT-11) COMBINED WITH CISPLATIN (C) GIVEN ONCE EVERY 3 WEEKS TO PATIENTS WITH SOLID TUMORS, Annals of oncology, 9, 1998, pp. 259-259
ORAL TOPOTECAN (T) ON A DAILY X 5 SCHEDULE IN COMBINATION WITH INTRAVENOUS CISPLATIN (C) - A PHASE-I AND PHARMACOLOGICAL STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS
Authors: DEJONGE MJA SPARREBOOM A PLANTING AST BROUWER E VANDERBURG MEL HEARN S VERWEIJ J
Citation: Mja. Dejonge et al., ORAL TOPOTECAN (T) ON A DAILY X 5 SCHEDULE IN COMBINATION WITH INTRAVENOUS CISPLATIN (C) - A PHASE-I AND PHARMACOLOGICAL STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS, Annals of oncology, 9, 1998, pp. 264-264
PHASE-I STUDY OF WEEKLY CISPLATIN (P) AND 4-WEEKLY OR WEEKLY TAXOL (T) - A HIGHLY-ACTIVE THERAPY IN FIRST AND 2ND LINE ADVANCED EPITHELIAL OVARIAN-CANCER (OC)
Authors: VANDERBURG MEL DEWIT R STOTER G VERWEIJ J
Citation: Mel. Vanderburg et al., PHASE-I STUDY OF WEEKLY CISPLATIN (P) AND 4-WEEKLY OR WEEKLY TAXOL (T) - A HIGHLY-ACTIVE THERAPY IN FIRST AND 2ND LINE ADVANCED EPITHELIAL OVARIAN-CANCER (OC), Annals of oncology, 9, 1998, pp. 376-376
DISPOSITION OF CREMOPHOR EL IN HUMANS LIMITS THE POTENTIAL FOR MODULATION OF THE MULTIDRUG-RESISTANCE PHENOTYPE IN-VIVO
Authors: SPARREBOOM A VERWEIJ J VANDERBURG MEL LOOS WJ VIGANO L LOCATELLI A NOOTER K STOTER G GIANNI L
Citation: A. Sparreboom et al., DISPOSITION OF CREMOPHOR EL IN HUMANS LIMITS THE POTENTIAL FOR MODULATION OF THE MULTIDRUG-RESISTANCE PHENOTYPE IN-VIVO, Annals of oncology, 9, 1998, pp. 551-551
HIGH PREVALENCE OF CODON 213(ARG-]STOP) MUTATIONS OF THE TP53 GENE INHUMAN OVARIAN-CANCER IN THE SOUTHWESTERN PART OF THE NETHERLANDS
Authors: SCHUYER M HENZENLOGMANS SC VANDERBURG MEL FIERET EJH KLIJN JGM FOEKENS JA BERNS EMJJ
Citation: M. Schuyer et al., HIGH PREVALENCE OF CODON 213(ARG-]STOP) MUTATIONS OF THE TP53 GENE INHUMAN OVARIAN-CANCER IN THE SOUTHWESTERN PART OF THE NETHERLANDS, International journal of cancer, 76(3), 1998, pp. 299-303
QUANTITATION OF CREMOPHOR EL IN HUMAN PLASMA SAMPLES USING A COLORIMETRIC DYE-BINDING MICROASSAY
Authors: SPARREBOOM A LOOS WJ VERWEIJ J DEVOS AI VANDERBURG MEL STOTER G NOOTER K
Citation: A. Sparreboom et al., QUANTITATION OF CREMOPHOR EL IN HUMAN PLASMA SAMPLES USING A COLORIMETRIC DYE-BINDING MICROASSAY, Analytical biochemistry, 255(2), 1998, pp. 171-175
PHASE-II STUDY OF WEEKLY 4'-EPIDOXORUBICIN IN PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE CERVIX - AN EORTC GYNECOLOGICAL CANCER COOPERATIVE GROUP-STUDY
Authors: VANDERBURG MEL BOLIS G BAKKER PJM CURRAN D SAHMOUD T VERMORKEN JB
Citation: Mel. Vanderburg et al., PHASE-II STUDY OF WEEKLY 4'-EPIDOXORUBICIN IN PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE CERVIX - AN EORTC GYNECOLOGICAL CANCER COOPERATIVE GROUP-STUDY, European journal of cancer, 33(9), 1997, pp. 1513-1515
WEEKLY HIGH-DOSE CISPLATIN (P) AND DAILY ORAL VEPESID (VP) - A HIGHLY-ACTIVE SALVAGE REGIMEN FOR PROGRESSIVE OR RECURRENT OVARIAN-CANCER AFTER PLATINUM THERAPY
Authors: VANDERBURG MEL LOGMANS A DEWIT R VANLENT M KRUIT WHJ STOTER G VERWEIJ J
Citation: Mel. Vanderburg et al., WEEKLY HIGH-DOSE CISPLATIN (P) AND DAILY ORAL VEPESID (VP) - A HIGHLY-ACTIVE SALVAGE REGIMEN FOR PROGRESSIVE OR RECURRENT OVARIAN-CANCER AFTER PLATINUM THERAPY, European journal of cancer, 33, 1997, pp. 529-529
PHARMACOKINETICS AND ORAL BIOAVAILABILITY OF 9-AMINO-CAMPTOTHECIN PEG1000 CAPSULES
Authors: SPARREBOORN A DEJONGE MJA LOOS WJ VANBEURDEN V PUNT CJA PLANTING AST VANDERBURG MEL COLAJORI E VERWEIJ J
Citation: A. Sparreboorn et al., PHARMACOKINETICS AND ORAL BIOAVAILABILITY OF 9-AMINO-CAMPTOTHECIN PEG1000 CAPSULES, European journal of cancer, 33, 1997, pp. 1112-1112
PHASE-I AND PHARMACOKINETIC (PK) STUDY OF IRINOTECAN (CPT-11) AND CISPLATIN IN PATIENTS WITH SOLID TUMORS - PRELIMINARY-RESULTS
Authors: DEJONGE MJA SPARREBOOM A PLANTING AST VANDERBURG MEL DEBRUIJN P BROUWER E VANBEURDEN V VANDUIJN MR JACQUES C VERWEIJ J
Citation: Mja. Dejonge et al., PHASE-I AND PHARMACOKINETIC (PK) STUDY OF IRINOTECAN (CPT-11) AND CISPLATIN IN PATIENTS WITH SOLID TUMORS - PRELIMINARY-RESULTS, European journal of cancer, 33, 1997, pp. 1134-1134
MORE THAN 20 YEARS 2ND-LOOK SURGERY IN ADVANCED EPITHELIAL OVARIAN-CANCER - WHAT DID WE LEARN
Authors: VANDERBURG MEL
Citation: Mel. Vanderburg, MORE THAN 20 YEARS 2ND-LOOK SURGERY IN ADVANCED EPITHELIAL OVARIAN-CANCER - WHAT DID WE LEARN, Annals of oncology, 8(7), 1997, pp. 627-629
DIFFERENTIAL MODULATION OF CISPLATIN ACCUMULATION IN LEUKOCYTES AND TUMOR-CELL LINES BY THE PACLITAXEL VEHICLE CREMOPHOR EL
Authors: DEVOS AI NOOTER K VERWEIJ J LOOS WL BROUWER E DEBRUIJN P RUIJGROK EJ VANDERBURG MEL STOTER G SPARREBOOM A
Citation: Ai. Devos et al., DIFFERENTIAL MODULATION OF CISPLATIN ACCUMULATION IN LEUKOCYTES AND TUMOR-CELL LINES BY THE PACLITAXEL VEHICLE CREMOPHOR EL, Annals of oncology, 8(11), 1997, pp. 1145-1150
PHASE-I AND PHARMACOLOGICAL STUDY OF DOCETAXEL AND CISPLATIN IN PATIENTS WITH ADVANCED SOLID TUMORS
Authors: PRONK LC SCHELLENS JHM PLANTING AST VANDENBENT MJ HILKENS PHE VANDERBURG MEL DEBOERDENNERT M MA J BLANC C HARTEVELD M BRUNO R STOTER G VERWEIJ J
Citation: Lc. Pronk et al., PHASE-I AND PHARMACOLOGICAL STUDY OF DOCETAXEL AND CISPLATIN IN PATIENTS WITH ADVANCED SOLID TUMORS, Journal of clinical oncology, 15(3), 1997, pp. 1071-1079
A SCORING SYSTEM FOR IMMUNOHISTOCHEMICAL STAINING - CONSENSUS REPORT OF THE TASK-FORCE FOR BASIC RESEARCH OF THE EORTC-GCCG
Authors: VANDIEST PJ VANDAM P HENZENLOGMANS SC BERNS E VANDERBURG MEL GREEN J VERGOTE I
Citation: Pj. Vandiest et al., A SCORING SYSTEM FOR IMMUNOHISTOCHEMICAL STAINING - CONSENSUS REPORT OF THE TASK-FORCE FOR BASIC RESEARCH OF THE EORTC-GCCG, Journal of Clinical Pathology, 50(10), 1997, pp. 801-804
PHASE-II STUDY OF A SHORT-COURSE OF WEEKLY HIGH-DOSE CISPLATIN COMBINED WITH LONG-TERM ORAL ETOPOSIDE IN METASTATIC MALIGNANT-MELANOMA
Authors: PLANTING AST VANDERBURG MEL GOEY SH SCHELLENS JHM VECHT C DEBOERDENNERT M STOTER G VERWEIJ J
Citation: Ast. Planting et al., PHASE-II STUDY OF A SHORT-COURSE OF WEEKLY HIGH-DOSE CISPLATIN COMBINED WITH LONG-TERM ORAL ETOPOSIDE IN METASTATIC MALIGNANT-MELANOMA, European journal of cancer, 32A(11), 1996, pp. 2026-2028
PHASE-II STUDY OF A CLOSELY SPACED IFOSFAMIDE-CISPLATIN SCHEDULE WITHTHE ADDITION OF G-CSF IN ADVANCED NON-SMALL-CELL LUNG-CANCER AND MALIGNANT-MELANOMA
Authors: PLANTING AST DEWIT R VANDERBURG MEL STOTER G VERWEIJ J
Citation: Ast. Planting et al., PHASE-II STUDY OF A CLOSELY SPACED IFOSFAMIDE-CISPLATIN SCHEDULE WITHTHE ADDITION OF G-CSF IN ADVANCED NON-SMALL-CELL LUNG-CANCER AND MALIGNANT-MELANOMA, Annals of oncology, 7(10), 1996, pp. 1080-1082
PHASE-II AND PHARMACOLOGICAL STUDY OF TOPOTECAN ADMINISTERED AS A 21-DAY CONTINUOUS-INFUSION TO PATIENTS WITH COLORECTAL-CANCER
Authors: CREEMERS GJ GERRITS CJH SCHELLENS JHM PLANTING AST VANDERBURG MEL VANBEURDEN VM DEBOERDENNERT M HARTEVELD M LOOS W HUDSON I STOTER G VERWEIJ J
Citation: Gj. Creemers et al., PHASE-II AND PHARMACOLOGICAL STUDY OF TOPOTECAN ADMINISTERED AS A 21-DAY CONTINUOUS-INFUSION TO PATIENTS WITH COLORECTAL-CANCER, Journal of clinical oncology, 14(9), 1996, pp. 2540-2545
ANALYSIS OF CUMULATIVE PROBABILITIES SHOWS THAT THE EFFICACY OF 5HT(3) ANTAGONIST PROPHYLAXIS IS NOT MAINTAINED
Authors: DEWIT R SCHMITZ PIM VERWEIJ J DEBOERDENNERT M DEMULDER PHM PLANTING AST VANDERBURG MEL STOTER G
Citation: R. Dewit et al., ANALYSIS OF CUMULATIVE PROBABILITIES SHOWS THAT THE EFFICACY OF 5HT(3) ANTAGONIST PROPHYLAXIS IS NOT MAINTAINED, Journal of clinical oncology, 14(2), 1996, pp. 644-651
DOCETAXEL AND PACLITAXES INHIBIT DNA ADDUCT FORMATION AND INTRACELLULAR ACCUMULATION OF CISPLATIN IN HUMAN-LEUKOCYTES
Authors: MA JG VERWEIJ J PLANTING AST KOLKER HJ LOOS WJ DEBOERDENNERT M VANDERBURG MEL STOTER G SCHELLENS JHM
Citation: Jg. Ma et al., DOCETAXEL AND PACLITAXES INHIBIT DNA ADDUCT FORMATION AND INTRACELLULAR ACCUMULATION OF CISPLATIN IN HUMAN-LEUKOCYTES, Cancer chemotherapy and pharmacology, 37(4), 1996, pp. 382-384
EXPRESSION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (UPA) AND ITS INHIBITOR PAI-1 IN BENIGN, BORDERLINE, MALIGNANT PRIMARY AND METASTATIC OVARIAN-TUMORS
Authors: VANDERBURG MEL HENZENLOGMANS SC BERNS EMJJ VANPUTTEN WLJ KLIJN JGM FOEKENS JA
Citation: Mel. Vanderburg et al., EXPRESSION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (UPA) AND ITS INHIBITOR PAI-1 IN BENIGN, BORDERLINE, MALIGNANT PRIMARY AND METASTATIC OVARIAN-TUMORS, International journal of cancer, 69(6), 1996, pp. 475-479
SPORADIC CDKN2 (MTS1 P16(INK4)) GENE ALTERATIONS IN HUMAN OVARIAN-TUMORS/
Authors: SCHUYER M VANSTAVEREN IL KLIJN JGM VANDERBURG MEL STOTER G HENZENLOGMANS SC FOEKENS JA BERNS EMJJ
Citation: M. Schuyer et al., SPORADIC CDKN2 (MTS1 P16(INK4)) GENE ALTERATIONS IN HUMAN OVARIAN-TUMORS/, British Journal of Cancer, 74(7), 1996, pp. 1069-1073
Risultati: 1-25 | 26-49